|
Patent landscape, scope, and claims: |
United States Patent 11,192,895 (Ponatinib HCl Crystalline Form) Scope, Claim Coverage, and US Patent Landscape
United States Patent 11,192,895 claims narrow crystalline-phase embodiments of ponatinib hydrochloride defined by specific X-ray powder diffraction (XRPD) peak sets, used to treat multiple CML/ALL disease-phase indications (chronic, acute, blast, Philadelphia chromosome positive acute lymphoblastic leukemia), including settings for prior tyrosine-kinase inhibitor (TKI) resistance/intolerance and BCR-ABL kinase-domain mutation. The claim strategy is an “API crystal identity” pivot: infringement turns on whether the administered drug product contains crystalline ponatinib hydrochloride meeting the XRPD-pattern constraints (and, in dependent claims, Form A).
What patents protect ponatinib hydrochloride crystalline XRPD forms in the US?
Answer: US 11,192,895 protects methods of treatment using ponatinib hydrochloride that is crystalline and meets defined XRPD peak-pattern requirements, with dependent claims narrowing to crystalline Form A and extending across multiple leukemia phases and mutation/therapy-resistance qualifiers.
How does US 11,192,895 define the protected “crystal”?
The core independent claim (Claim 1) is a method of treatment where the pharmaceutical composition includes at least one crystalline form of ponatinib hydrochloride characterized by XRPD. The XRPD characterization is written as multiple selectable peak lists (a)-(j), each requiring at least three 2θ values (±0.3) drawn from defined candidate sets, plus two “substantially as shown” pattern references to FIG. 41 labels.
Concretely, the claim’s XRPD element is satisfied if the administered ponatinib HCl crystalline material produces an XRPD pattern that conforms to one of the enumerated peak sets and/or the figure-referenced patterns.
XRPD “route map” in Claim 1 (independent scope)
- (a) at least three 2θ values (±0.3) chosen from: 5.9, 7.1, 10.0, 12.5, 13.6, 14.1, 15.0, 16.4, 17.7, 18.6, 19.3, 20.4, 21.8, 22.3, 23.8, 24.9, 26.1, 27.0, 28.4, 30.3, 31.7, 35.1
- (b) at least three chosen from: 3.1, 6.5, 12.4, 13.8, 15.4, 16.2, 17.4, 18.0, 20.4, 23.2, 24.4, 26.1, 26.9
- (c) at least three chosen from: 3.1, 6.5, 12.4, 13.8, 17.4, 18.0, 20.6, 22.0, 23.0, 25.5, 26.5, 27.4, 28.4, 29.0
- (d) at least three chosen from: 8.2, 10.1, 10.9, 14.9, 16.0, 16.3, 16.8, 17.7, 18.7, 20.2, 22.9, 24.0, 25.6, 26.7, 28.5
- (e) XRPD pattern substantially as shown in FIG. 41 labeled HC11+HC14 (GRP1.1)
- (f) at least three chosen from: 7.9, 8.7, 9.7, 11.4, 15.6, 16.5, 25.8
- (g) XRPD pattern substantially as shown in FIG. 41 labeled HC15b (VDS28.2)
- (h) at least three chosen from: 8.0, 10.2, 10.9, 11.8, 14.1, 15.4, 16.3, 19.9, 22.3, 23.7, 25.0, 28.2
- (i) at least three chosen from: 6.1, 7.0, 13.3, 16.4, 20.7, 22.2, 23.9, 25.5, 29.1
- (j) at least three chosen from: 6.1, 7.4, 13.5, 17.4, 18.5, 20.7, 23.9, 28.3
Key implication: even though the claim recites “at least one crystalline form,” infringement can still be triggered by a crystalline ponatinib HCl material that matches any one of the (a)-(j) pattern-definitions, not necessarily all.
What dependent claims tighten coverage to Form A?
- Claim 5: composition comprises crystalline Form A of ponatinib hydrochloride.
- Claim 6: composition consists essentially of crystalline Form A of ponatinib hydrochloride.
Key implication: Claim 5 requires the presence of Form A; Claim 6 reduces coexistence flexibility (“consists essentially of”) and can matter for evidentiary positions if a product includes Form A plus other polymorphs/hydrates.
Which leukemia indications does US 11,192,895 cover in the US?
Answer: The asserted methods cover:
- Chronic phase CML (Claim 1)
- Acute phase CML (Claim 7)
- Blast phase CML (Claim 13)
- Philadelphia chromosome positive acute lymphoblastic leukemia (Claim 19)
Each indication is tied to administration of a therapeutically effective amount of a composition with the same XRPD-defined crystalline ponatinib hydrochloride element.
Do the disease-phase dependent claim trees change the crystallinity scope?
No. For each phase, the XRPD element repeats the same (a)-(j) structure and the same figure-labeled XRPD options. The practical coverage differentiator comes from the clinical indication label and the dependent qualifiers (TKI resistance/intolerance, BCR-ABL mutation, Form A).
What patents claims protect TKI-resistant or BCR-ABL mutation-driven disease?
Answer: Dependent claims add two additional clinical qualifiers that preserve the XRPD-defined crystal requirement.
TKI resistance/intolerance
- Claim 2: subject is resistant or intolerant to at least one prior TKI
- Claim 3: resistant or intolerant to at least two prior TKIs
- Parallel language appears for acute and blast phase trees:
- Claims 8-9
- Claims 14-15
- Claims 20-21 (for Ph+ ALL)
Scope effect: if a product is used to treat eligible patients meeting these resistance criteria, the dependent claims provide an additional infringement hook that is not present in the base indication-only method.
BCR-ABL kinase domain mutation
- Claim 4: leukemia results from mutation in the Bcr-Abl kinase domain
- Parallel language appears in each disease-phase tree:
Scope effect: these claims are narrower on patient subpopulation but can be pivotal in enforcement if the accused product is used off-label or across mixed populations.
How strong is the patent estate for crystalline ponatinib hydrochloride under US 11,192,895 claim structure?
Answer: Strength in this patent is concentrated in the crystallinity identity constraint (XRPD peak sets with ±0.3 tolerance and figure-based patterns) plus indication-based therapeutic method. The multiple (a)-(j) alternatives and permissive “at least three peaks” structure can broaden the range of XRPD patterns that still meet the claim element.
Why “at least three 2θ values” broadens practical infringement risk
Each selectable subpart (a)-(d), (f), (h)-(i), (j) is satisfied by any subset of at least three peaks from a larger list. That structure can allow variable peak intensities, measurement conditions, and dataset differences while still clearing the minimum peak-count requirement.
Why the “substantially as shown in FIG. 41” elements increase evidentiary complexity
Substantially-as-shown language tends to invite expert-driven claim construction and comparative XRPD interpretation. The two explicit figure labels:
- HC11+HC14 (GRP1.1) via (e)
- HC15b (VDS28.2) via (g)
create two “anchor patterns” that can be used to show equivalency even if exact peak participation differs, depending on how “substantially” is construed in litigation.
What would a generic or authorized competitor need to avoid to steer clear of US 11,192,895?
Answer: The infringement pivot is whether the competitor’s ponatinib hydrochloride (in its crystalline form present in the administered composition) meets the XRPD constraints in (a)-(j) and/or the FIG. 41 anchored patterns. A design-around must therefore change the crystalline identity such that the XRPD peak-set requirements are not met.
Design-around levers implied by the claim language
- Use a ponatinib HCl crystalline form whose XRPD peak sets do not overlap sufficiently with the enumerated candidate sets under the “at least three peaks (±0.3)” rule.
- Ensure the XRPD pattern does not align substantially with FIG. 41 HC11+HC14 (GRP1.1) and/or HC15b (VDS28.2).
- Avoid crystalline Form A if attempting to defeat dependent claims:
- Claims requiring “comprises crystalline Form A” (Claim 5, 11, 17, 23)
- Claims requiring “consists essentially of crystalline Form A” (Claim 6, 12, 18, 24)
Manufacturing/IP barrier profile for “crystal switching”
Because the claim is constrained to XRPD measurement outcomes, standard polymorph/hydrate control programs become IP-relevant. Even if the active has the same chemical entity (ponatinib HCl), changing the solid-state form can place the product outside the defined XRPD envelope.
What US 11,192,895 says about pharmaceutical composition scope (form, composition boundary, administration)
Answer: The claim is a method claim, so it attaches to administration of a therapeutically effective amount of a composition with the defined crystallinity. The composition language is minimal beyond solid-state identity:
- Claim 1: composition comprising at least one crystalline form of ponatinib hydrochloride characterized by the XRPD constraints
- Claims 5-6 and parallel: crystalline Form A and “consists essentially of” Form A
Practical reading: excipients and dosage forms are not specified in the independent claims you provided; infringement likely turns on the solid-state form of ponatinib hydrochloride present in the administered drug product.
How does US 11,192,895 compare with typical ponatinib IP protections (composition vs method vs polymorph identity)?
Answer: Compared with broad “ponatinib use” patents, US 11,192,895 is more specific because it requires the administered ponatinib HCl to be a crystalline form that matches defined XRPD patterns. That specificity can reduce overlap with generic products that use a different solid-state form, but it also can expand enforcement if multiple crystalline preparations satisfy the same XRPD constraints.
Claim coverage geometry
- Broad axis: multiple leukemia phases and multiple patient subpopulations (TKI resistance and BCR-ABL mutations)
- Narrowing axis: XRPD pattern constraints with ±0.3 tolerances and minimum peak-count
Patent landscape deliverable: what can be concluded from the provided information (and what cannot)
Answer: The provided content contains the full claim-set language for US 11,192,895 but does not include:
- application publication numbers, filing date, priority, assignee
- prosecution history
- related US patents in the ponatinib polymorph family
- Orange Book listings, FDA approval dates, or patent expiry/exclusivity timelines
- PTAB status, district court cases, or licensing/settlement records
- claim construction rulings
Since those are not included in the input, no defensible cross-patent landscape map (other than the internal scope of this single patent) can be produced without importing external data.
Key Takeaways
- US 11,192,895 is a method-of-treatment patent centered on crystalline ponatinib hydrochloride XRPD-defined identity.
- The independent claim covers chronic phase CML, while separate independent claims extend coverage to acute phase CML, blast phase CML, and Philadelphia chromosome positive acute lymphoblastic leukemia.
- The XRPD element uses multiple alternative peak-pattern definitions (a)-(j) with “at least three peaks (±0.3)” and two FIG. 41 “substantially as shown” anchors, which broadens potential infringement across compliant crystal lots.
- Dependent claims add TKI resistance/intolerance and BCR-ABL kinase domain mutations patient qualifiers, plus crystalline Form A and “consists essentially of Form A” composition refinements.
FAQs
- Does US 11,192,895 require the accused product to contain “crystalline Form A” to infringe?
- How can “at least three 2θ values (±0.3)” affect infringement analysis for ponatinib XRPD measurements?
- What is the practical scope of the FIG. 41 “substantially as shown” XRPD references in US 11,192,895?
- Do the TKI resistance and BCR-ABL mutation limitations function as separate infringement requirements or additional qualifiers for specific patient subsets?
- If a competitor changes ponatinib solid state form to avoid the enumerated XRPD sets, does US 11,192,895 still apply to all leukemia phases?
References (APA)
- United States Patent No. 11,192,895 (claims provided in prompt).
More… ↓
⤷ Start Trial
|
